U.S. Markets closed
  • S&P Futures

    3,443.75
    +11.50 (+0.34%)
     
  • Dow Futures

    28,268.00
    +86.00 (+0.31%)
     
  • Nasdaq Futures

    11,700.75
    +40.00 (+0.34%)
     
  • Russell 2000 Futures

    1,619.80
    +5.00 (+0.31%)
     
  • Crude Oil

    41.51
    +0.05 (+0.12%)
     
  • Gold

    1,915.60
    +0.20 (+0.01%)
     
  • Silver

    24.92
    -0.06 (-0.22%)
     
  • EUR/USD

    1.1837
    +0.0008 (+0.0710%)
     
  • 10-Yr Bond

    0.7970
    +0.0360 (+4.73%)
     
  • Vix

    29.35
    +0.17 (+0.58%)
     
  • GBP/USD

    1.2961
    +0.0014 (+0.1063%)
     
  • USD/JPY

    105.4450
    -0.0250 (-0.0237%)
     
  • BTC-USD

    11,909.05
    +852.04 (+7.71%)
     
  • CMC Crypto 200

    239.21
    +0.30 (+0.12%)
     
  • FTSE 100

    5,889.22
    +4.57 (+0.08%)
     
  • Nikkei 225

    23,567.04
    0.00 (0.00%)
     

Portnoy Law: Lawsuit Filed On Behalf of Nextcure, Inc. Investors

Portnoy Law
·2 mins read

Investors with a $100,000 or more in losses are encouraged to contact the firm.

Click here to join the case

LOS ANGELES, Oct. 08, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Nextcure, Inc. ("Nextcure" or "the Company") (NASDAQ: NXTC) investors that acquired securities between November 5, 2019 and July 14, 2020.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

NextCure disclosed on January 13, 2020 that Eli Lilly and Company had ended its collaboration agreement for the research and development of NC318, Nextcure’s leading product candidate, a first-in-class immunomedicine targeting the Siglec-15 immunomodulatory receptor, particularly for patients with advanced or metastatic solid tumors.

On January 13, 2020, Nextcure's share price fell $4.70, or 8%, on this news, to close at $52.00 per share, injuring investors.

Then, on July 13, 2020, before the market opened, NextCure announced that it was no longer planning to "advance the non-small cell lung cancer (NSCLC) and ovarian cancer cohorts in the stage 2 portion of the Simon 2-stage trial." Nextgen announced the resignation of its Chief Medical Officer on the same day.

On July 13, 2020, Nextcure's share price fell $9.73, or 54%, on this news to close at $8.15 per share, injuring investors further.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising